Bristol Myers Squibb (BMY) Q1 2023: New Product Sales Double, Diversification Accelerates Pipeline Renewal
Bristol Myers Squibb’s Q1 marked a pivotal acceleration in portfolio renewal as new product sales more than doubled, offsetting legacy headwinds and positioning the company for a more diversified growth trajectory. Management’s confidence in new launches and pipeline progress was clear, but execution on access, manufacturing, and payer negotiations will be critical levers to watch through 2023 and beyond.
Summary
- Portfolio Renewal Momentum: New product launches are rapidly scaling, setting up a shift in revenue mix.
- Operational Leverage: Manufacturing and market access investments are central to sustaining growth beyond legacy losses.
- Leadership Transition Watch: Incoming CEO inherits a pipeline-rich, but execution-dependent, next chapter.
Business Overview
Bristol Myers Squibb (BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines in oncology, hematology, cardiovascular, and immunology. The company’s revenue is generated through branded prescription drugs, with major segments including oncology (e.g., Opdivo, Abecma), cardiovascular (Eliquis, Camzyos), hematology (Revlimid, Reblozyl), and immunology (Zeposia, Sotyktu). The business model relies on both established “in-line” brands and a growing portfolio of recently launched, high-growth therapies.
Performance Analysis
BMY’s Q1 results underscored the company’s ongoing transition from legacy blockbusters to a diversified growth engine led by new product launches. Total revenue was driven by double-digit growth in both in-line and new product portfolios, with the latter more than doubling year-over-year and now exceeding $720 million in quarterly sales. This expansion was powered by strong commercial execution in oncology (notably Opdivo, Opdualag, Abecma, Breyanzi), cardiovascular (Eliquis, Camzyos), and immunology (Zeposia, Sotyktu).
Legacy headwinds remain material, particularly from generic erosion of Revlimid, which continues to introduce quarter-to-quarter variability. However, management emphasized that new and in-line products are now more than offsetting these losses. Gross margin was pressured by product mix, though partially cushioned by one-time FX hedging gains. Operating expenses were stable, with a notable decline in MS&A due to spend timing, expected to reverse as investment ramps for new launches.
- New Product Portfolio Scaling: Over $720 million in Q1 sales, up more than 100% YoY, with sequential growth above 11%.
- Oncology Engines: Opdivo global sales grew double digits, with U.S. up 17%, and Opdualag’s launch surpassed a 20% market share in first-line melanoma.
- Cardiovascular Strength: Eliquis U.S. sales rose 19% despite international generic pressure; Camzyos patient enrollment and REMS certification expanded rapidly.
Cash flow from operations reached $3 billion, enabling continued debt reduction and leaving ample firepower for business development and opportunistic buybacks. The reaffirmed guidance signals management’s confidence in the trajectory of both top and bottom line growth, anchored by the ramp of recently launched and pipeline assets.
Executive Commentary
"During the quarter, our in-line brands and new product portfolio grew 8% or 10% adjusting for foreign exchange. Notably, revenue from our new product portfolio more than doubled compared to a year ago, reinforcing our confidence that we expect to roughly double revenue from these products this year."
Giovanni Caforio, Executive Chairman
"Total company sales in a quarter topped $11.3 billion, driven by strong double-digit sales of our in-line and new product portfolio, offset by Revlimid's loss of exclusivity. ... The new product portfolio generated over $720 million in sales, which more than doubled versus prior year, and grew over 11% sequentially."
David Elkins, Chief Financial Officer
Strategic Positioning
1. New Product Commercialization Drives Growth Mix Shift
BMY’s commercial execution is rapidly shifting the revenue base toward new launches, with products like Opdualag, Abecma, Sotyktu, and Camzyos scaling across key indications and geographies. The company’s ability to build market share, secure reimbursement, and expand prescriber bases is central to its growth thesis—especially as legacy products face generic erosion.
2. Pipeline Momentum and De-Risking
Pipeline progress is a defining theme, as BMY advanced multiple registrational studies, regulatory filings, and next-generation assets across oncology, cell therapy, and immunology. Notably, cell therapy leadership is reinforced by CARMA-3 filings and manufacturing capacity investments, while Sotyktu’s broad development program in psoriasis, arthritis, and lupus underpins a $4 billion revenue ambition.
3. Manufacturing and Supply Chain as Growth Enablers
Manufacturing reliability and capacity expansions are critical to delivering on demand for cell therapies and new launches. The acquisition of a Libertyville vector facility and dual sourcing strategies are designed to support scale and resilience. Success here is essential to sustain commercial momentum and avoid bottlenecks as patient volumes rise.
4. Capital Allocation and Balance Sheet Flexibility
With $9 billion in cash and a two-times net debt-to-EBITDA ratio, BMY is positioned to pursue business development, dividend growth, and opportunistic share repurchases. Management reiterated that BD remains the top capital allocation priority, targeting both near-term and long-term growth avenues.
5. Navigating Payer and Pricing Dynamics
Market access and payer negotiations are increasingly pivotal, especially as U.S. government price setting (IRA) looms for Eliquis and new launches require formulary wins. The company’s discipline in rebate management and strategic focus on early access decisions will be a key determinant of commercial success in 2023 and 2024.
Key Considerations
This quarter’s results highlight a company at a strategic crossroads, balancing robust new product momentum with executional complexity and leadership transition. Investors should weigh the following:
Key Considerations:
- New Launch Execution Pace: Uptake and payer access for Sotyktu and Opdualag are setting the tone for future launches and market share gains.
- Cell Therapy Supply Chain: Reliability and capacity expansion in cell therapy manufacturing will determine the ability to meet demand and defend leadership in CAR-T.
- Legacy Revenue Drag: Revlimid’s generic erosion introduces ongoing revenue volatility, though management expects new products to more than offset this headwind.
- Leadership Transition: Chris Berner’s elevation to CEO places a proven commercial operator at the helm, but also brings execution risk as the company pivots to a new growth phase.
- Payer and Regulatory Headwinds: The evolving U.S. pricing landscape, especially IRA impact on Eliquis, will test BMY’s access strategies and margin resilience.
Risks
BMY faces material risks from ongoing generic erosion, particularly in Revlimid, and from the U.S. government’s price setting regime (IRA) targeting Eliquis. Execution risk is elevated as the company ramps multiple new launches, expands manufacturing, and navigates complex payer negotiations. Pipeline readouts and regulatory decisions remain binary events that could impact future growth, while leadership transition introduces uncertainty around strategic continuity.
Forward Outlook
For Q2 2023, BMY guided to:
- Operating expenses of approximately $4.2 billion, reflecting increased investment in launches.
- Gross margin to remain near 77% for the first half, with product mix as a key driver.
For full-year 2023, management reaffirmed guidance:
- Revenue growth of approximately 2% (reported and constant currency).
- Revlimid revenue expectation maintained at $6.5 billion, with ongoing quarter-to-quarter variability.
- Non-GAAP EPS range of $7.95 to $8.25.
Management highlighted several factors that will shape performance:
- Momentum in new product launches and in-line brands to offset legacy declines.
- Back-half weighted growth as launches ramp and market access expands.
Takeaways
BMY’s Q1 results confirm a decisive pivot to portfolio renewal, with new launches now materially contributing to growth. The company’s ability to execute on access, supply, and payer negotiations will determine how durable this momentum proves as legacy headwinds persist.
- New Product Scale: Rapid uptake in new launches is structurally shifting the revenue base, with pipeline catalysts providing further upside if execution holds.
- Execution Watchpoints: Manufacturing reliability, market access, and payer negotiations are now central to the growth story, especially in cell therapy and immunology.
- Leadership Transition: The incoming CEO’s commercial experience is well-aligned to current needs, but the transition period will test organizational agility and strategic discipline.
Conclusion
Bristol Myers Squibb’s Q1 marks a clear inflection in portfolio diversification, but the path forward hinges on flawless execution in launches, manufacturing, and market access. Investors should monitor access wins, supply chain progress, and regulatory events as the new leadership team takes the helm.
Industry Read-Through
BMY’s results reinforce several sector-wide themes: The industry’s shift from legacy blockbusters to diversified growth portfolios is accelerating, with commercial execution and supply chain resilience as key differentiators. The IRA’s impact on pricing and access is top of mind, and cell therapy’s operational complexity is becoming a litmus test for biopharma scale and reliability. Companies with robust pipelines and disciplined capital allocation are best positioned, but must navigate payer, regulatory, and manufacturing hurdles to fully realize the value of innovation.